Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Givaudan financials

This article was originally published in The Rose Sheet

Executive Summary

Fragrance division sales for the first nine months fell 1% to $579 mil. ($1=1.48 CHF) due to struggling fine fragrances, ingredients units, which offset "strong sales growth momentum" by consumer products, Geneva-based flavor and fragrance supplier reports Oct. 10. Firm's fine fragrance business was hurt by general market slowdown, with shortfall "spread proportionally across all clients and brands." Fragrance ingredients "continued to suffer from sustained price pressure on commodities, a further decrease of cosmetic ingredient sales and lower levels of sales to fine fragrance producers," firm says. Including full-year sales from recently acquired Nestle flavor business, pro forma consolidated revenues increased a slight .8% to $1.46 bil...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel